

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

POLL RESULTS OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING HELD ON 6 FEBRUARY 2026

The Company is pleased to announce that the resolutions set out in the notice of EGM and proposed at the EGM was duly passed by the Shareholders by way of poll at the EGM.

References are made to the notice of the 2026 first extraordinary general meeting (“**EGM**”) of China Resources Pharmaceutical Group Limited (the “**Company**”) dated 20 January 2026 and the circular of the Company of even date (the “**Circular**”) in relation to, among other things, (i) the continuing connected transactions contemplated under the Sales Framework Agreement 2026/2028; (ii) the proposed amendments to the Articles of Association; and (iii) the EGM. Unless otherwise specified, capitalized terms used herein shall have the same meanings as those defined in the Circular.

The Company is pleased to announce the poll results in respect of the resolutions proposed at the EGM as follows:

Ordinary Resolution proposed at the EGM	Number of Votes (%)	
	For	Against
1. “ THAT (a) the Sales Framework Agreement 2026/2028, a copy of which is tabled at the meeting and marked “A” and initialed by the chairman of the meeting for identification purpose, the terms thereof and the transactions and the Annual Caps contemplated thereunder be and are hereby approved, ratified and confirmed; and (b) any one Director be and is hereby authorized for and on behalf of the Company to execute, deliver and/or affix seal on all such other documents, instruments and agreements and to do all such acts or things deemed by him/her to be incidental to, ancillary to or in connection with the matters contemplated in the Sales Framework Agreement 2026/2028.”	1,420,245,890 (99.99%)	50,502 (0.01%)
The resolution was duly passed as an ordinary resolution.		

Special Resolution proposed at the EGM		Number of Votes (%)	
		For	Against
2.	“ THAT the New Articles of Association of the Company, a copy of which is tabled at the meeting and marked “B” and initialed by the chairman of the meeting for identification purpose be and are hereby approved and adopted in substitution for and to the exclusion of the existing Articles of Association of the Company with immediate effect after the close of this meeting, and any one Director be and is hereby authorised to do all things necessary to implement the adoption of the New Articles of Association.”	4,353,365,002 (99.99%)	50,500 (0.01%)
The resolution was duly passed as a special resolution.			

As at the date of the EGM, the total number of issued and fully paid up shares of the Company was 6,282,510,461 Shares.

In relation to the ordinary resolution proposed at the EGM, as disclosed in the Circular, CRH (Pharmaceutical) Limited and Commotra Company Limited, which are wholly-owned subsidiaries of CR Holdings, are directly interested in 3,354,786,612 Shares, representing approximately 53.40% of the issued share capital of the Company. CR Holdings is a controlling shareholder of each of the Company and CR Healthcare, and is therefore considered to have a material interest in the Sales Framework Agreement 2026/2028 and the transactions and the Annual Caps contemplated thereunder. Accordingly, CR Holdings and its associates were required to abstain, and had abstained, from voting on the ordinary resolution proposed at the EGM. Therefore, the total number of Shares entitling the Shareholders to attend and vote for or against the ordinary resolution proposed at the EGM was 2,927,723,849 Shares.

In relation to the special resolution proposed at the EGM, the total number of Shares entitling the Shareholders to attend and vote for or against the special resolution proposed at the EGM was 6,282,510,461 Shares.

As at the date of the EGM, the Company did not hold any treasury shares (including any treasury shares held or deposited with CCASS), and there are no repurchased Shares pending cancellation and should be excluded from the total number of issued Shares for the purpose of the EGM. Save as disclosed above, there were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions proposed at the EGM as set out in Rule 13.40 of the Listing Rules, and there were no Shares requiring the Shareholders to abstain from voting at the EGM under the Listing Rules. No Shareholders had stated their intention in the Circular to vote against or to abstain from voting on the resolutions proposed at the EGM.

Mr. Liu Changan, an executive Director of the Company, presided the EGM. The Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan, Mdm. Jiao Ruifang, Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen attended the EGM in person or via video conference, whilst Mr. Bai Xiaosong and Mr. Cheng Jie were unable to attend the EGM due to their other business commitments.

Tricor Investor Services Limited, the share registrar of the Company, acted as scrutineers for the vote-taking at the EGM.

Shareholders may refer to the Circular for details of the above resolutions proposed at the EGM. The Circular may be viewed and downloaded from the Company's website at www.crpharm.com or the website of the Stock Exchange at www.hkexnews.hk.

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 6 February 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Cheng Jie and Mr. Liu Changan as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.